James Fulmer
Philadelphia
Summary
Dynamic scientist with extensive experience in the pharmaceutical industry, specializing in the preclinical development of therapeutic antibodies. Proven track record in cell-based assay development and project management, successfully leading teams to significant advancements in cancer research. Expertise in data analysis and interpretation, complemented by strong collaboration skills to drive project success across cross-functional teams. Committed to advancing therapeutic innovations while maintaining high ethical standards and scientific integrity.
Overview
18
18
years of professional experience
Work History
SR. SCIENTIST
EISAI INC.
EXTON
07.2023 - 10.2024
- Spearheaded multiple phases of preclinical development for therapeutic monoclonal antibodies, ADCs, and bi-specific antibodies.
- Appointed project lead for initial discovery efforts into pancreatic ductal adenocarcinoma.
- Directed team of scientists conducting in vitro and in vivo experiments.
- Authored comprehensive study designs for the development of cell line-derived xenograft models and efficacy testing of drug candidates.
- Managed project coordination, handling scale-up of cell cultures, procurement of reagents, and inoculation scheduling.
SCIENTIST
EISAI INC.
EXTON
07.2018 - 07.2023
- Planned, optimized, and executed complex in vitro experiments to provide proof of concept and translational evidence (cytotoxicity, bystander effects, neutropenia, immunogenic cell death).
- Executed ex vivo experiments to assess the effect of T-cell engaging bi-specific antibodies, or combination therapies involving ADCs, and immune checkpoint inhibitors.
- Analyzed samples using flow cytometry (immunophenotyping), ELISA, and functional proteomics experiments (Luminex, IsoPlexis IsoLight).
- Implemented detailed FACS profiling and cytotoxicity experiments for identifying applicable ADC treatments.
SR. PRINCIPAL RESEARCHER
EISAI INC.
EXTON
06.2012 - 07.2018
- Screened T-cell engaging bi-specific antibodies using various functional cell-based assays.
- Used siRNA to study the role of endosialin in PDGF receptor signaling, and cell proliferation in pericytes.
- Used advanced screening techniques—ADCC, CDC, ELISA, FACS, immunoblotting, and binding affinity analyses—to select optimal antibody clones.
- Researched the expression and function of FRδ in human regulatory T cells.
- Developed an assay to test the function of FRδ antibodies in a typical human immune response.
- Performed transfection studies with human T cells to determine the fate of cells expressing FRδ.
SR. RESEARCHER
EISAI INC.
EXTON
03.2007 - 06.2012
- Doubled the antibody production of hybridoma cell lines by modulating the DNA mismatch repair process, FACS sorting for high-expressing clones, and screening with high-throughput assays.
- Improved a method for developing hybridoma cell lines, optimizing an in vitro germinal center reaction.
- Determined the best procedures for PBMC isolation from whole blood, cell separation, immune complex generation, and fusion partners and parameters.
- Optimized a micro-neutralization assay to screen antibodies that are able to neutralize a broad range of HIV viruses.
Education
B.S. - Biology
Skills
- Cell culture and aseptic technique
- Cell-based assay development
- Human tissue handling
- PBMC isolation and profiling
- Live-cell imaging
- Multi-color flow cytometry (FACS)
- PCR, RT-PCR
- Western blotting
- ELISA, HTRF
- Multiplex molecular-based assays (Luminex)
- Scientific writing
- Animal study direction and coordination
- Junior scientist mentoring and supervision
- Inventory management
- Laboratory and radiation safety
- Contract research organization (CRO) management
- Project management
- Antibody and ADC characterization
- Research proposals, technical reports
- Standard operating procedures (SOPs)
- Electronic laboratory notebook (IDBS)
Publications
- Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity., Wang Y, Xia B, Cao L, Yang J, Feng C, Jiang F, Li C, Gu L, Yang Y, Tian J, Cheng X, Furuuchi K, Fulmer J, Verdi A, Rybinski K, Soto A, Albone E, Uenaka T, Gong L, Liu T, Qin Q, Wei Z, Zhou Y., Antibody Therapeutics, 7, 3, 221-232, 2024
- Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models., Furuuchi K, Rybinski K, Fulmer J, Moriyama T, Drozdowski B, Soto A, Fernando S, Wilson K, Milinichik A, Dula ML, Tanaka K, Cheng X, Albone E, Uenaka T., Cancer Science, 112, 6, 2467-2480, 2021
- Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature., Rybinski K, Imtiyaz HZ, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, Fernando S, Henry M, Chao Q, Kline B, Albone E, Wustner J, Lin J, Nicolaides NC, Grasso L, Zhou Y., Oncotarget, 6, 28, 25429-40, 2015
- Biomechanical and biologic effects of meniscus stabilization using triglycidyl amine., Hunter SA, Rapoport HS, Connolly JM, Alferiev I, Fulmer J, Murti BH, Herfat M, Noyes FR, Butler DL, Levy RJ., J Biomedical Materials Research A, 93, 1, 235-42, 2010
- Fenfluramine disrupts the mitral valve interstitial cell response to serotonin., Connolly JM, Bakay MA, Fulmer JT, Gorman RC, Gorman JH 3rd, Oyama MA, Levy RJ., American Journal of Pathology, 175, 3, 988-97, 2009
- Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol., Stachelek SJ, Alferiev I, Fulmer J, Ischiropoulos H, Levy RJ., J Biomedical Materials Research A, 82, 4, 1004-11, 2007
- Foxl1-Cre BAC transgenic mice: a new tool for gene ablation in the gastrointestinal mesenchyme., Sackett SD, Fulmer JT, Friedman JR, Kaestner KH., Genesis, 45, 8, 518-22, 2007
- Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic mall with triglycidylamine/mercapto bisphosphonate., Rapoport HS, Connolly JM, Fulmer J, Dai N, Murti BH, Gorman RC, Gorman JH, Alferiev I, Levy RJ., Biomaterials, 28, 4, 690-9, 2007
- The initiation of liver development is dependent on Foxa transcription factors., Lee CS, Friedman JR, Fulmer JT, Kaestner KH., Nature, 435, 7044, 944-7, 2005
- The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion., Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, Kaestner KH., J Clinical Investigation, 115, 4, 1006-15, 2005
- Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency., Behr R, Brestelli J, Fulmer JT, Miyawaki N, Kleyman TR, Kaestner KH., J Biological Chemistry, 279, 40, 41936-41, 2004
Timeline
SR. SCIENTIST - EISAI INC.
07.2023 - 10.2024
SCIENTIST - EISAI INC.
07.2018 - 07.2023
SR. PRINCIPAL RESEARCHER - EISAI INC.
06.2012 - 07.2018
SR. RESEARCHER - EISAI INC.
03.2007 - 06.2012
Bucknell University - B.S., Biology
Similar Profiles
Joann CorazzelliJoann Corazzelli
Senior Oncology Account Manager at Eisai PharmaceuticalsSenior Oncology Account Manager at Eisai Pharmaceuticals
Sumit KumarSumit Kumar
Manager-Pharmacovigilance at Eisai Pharmaceuticals India Pvt LtdManager-Pharmacovigilance at Eisai Pharmaceuticals India Pvt Ltd
RAJA CHAITANYA VIKRAMRAJA CHAITANYA VIKRAM
Project Manager - CMC (Program Manager) at Eisai Pharmaceuticals India Pvt ltdProject Manager - CMC (Program Manager) at Eisai Pharmaceuticals India Pvt ltd